Efficacy News and Research

RSS

Behavioral stress accelerates prostate cancer development in mice

Prostate cancer patients have increased levels of stress and anxiety; however, several recent studies have found that men who take drugs that interfere with the stress hormone adrenaline have a lower incidence of prostate cancer.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Reducing the level of mutant p53 gene increases susceptibility to cancer treatment

Scientists from the National Cancer Centre Singapore (NCCS) have discovered the workings of the gene that has been hindering treatment response in cancer patients. This discovery was made after 5 years of studying the mutant form of the p53 gene, the major tumor suppressor in humans, which is generally found mutated in over 50% of all type of human cancers.

27 Jan 2013

FDA updates metal-on-metal hip replacement advice

The US Food and Drug Administration has updated its advice on the use of metal-on-metal hip replacement prostheses.

25 Jan 2013

Antibiotic use common at the end of life

More than one-quarter of hospice patients receive antibiotics in their last week of life, despite the absence of documented infection in most cases, US researchers report.

25 Jan 2013

Efficacy of docusate called into question

Docusate does not significantly improve the management of constipation in hospice patients, show the results of a randomized, placebo-controlled trial.

25 Jan 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

Researchers study innovative stem cell drug for treating localized cartilage damage

Rush University Medical Center is conducting the nation's first clinical study of an innovative stem cell drug, Cartistem, to repair knee cartilage damaged by aging, trauma or degenerative diseases such as osteoarthritis.

25 Jan 2013

Findings could help explain prevalence of urinary tract infections in post-menopausal women

Researchers from Washington University School of Medicine, St. Louis, show that reservoirs of uropathogenic E. coli within the bladder exist in higher numbers post-menopause than pre-menopause in a mouse model, a finding that could help explain the greater prevalence of urinary tract infections in post-menopausal women.

25 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina. Inherited retinal degenerative diseases were previously considered untreatable and incurable.

23 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

IntelliCell BioSciences, Inc. announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells."

23 Jan 2013

Hospital-based home care can work for children with cancer

Hospital-based home care is a feasible alternative for children with cancer both regarding price and efficacy, show study findings.

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

22 Jan 2013

Gene therapy improves vision but does not halt progression of cell loss

22 Jan 2013

Kaiser Permanente study examines increasing prevalence of undervaccination

In a new study published today in JAMA Pediatrics (formerly Archives of Pediatrics and Adolescent Medicine), Kaiser Permanente researchers found that 49 percent of children ages 2-24 months did not receive all recommended vaccinations or did not get vaccinated according to the Advisory Committee on Immunization Practices schedule.

22 Jan 2013

Cordis presents two-year STROLL study results at ISET 2013

Cordis Corporation today announced the presentation of the two-year STROLL study results at the Abstracts and Late Breaking Clinical Trials session at ISET 2013.

22 Jan 2013

Efficacy News and Research

Behavioral stress accelerates prostate cancer development in mice

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Reducing the level of mutant p53 gene increases susceptibility to cancer treatment

FDA updates metal-on-metal hip replacement advice

Antibiotic use common at the end of life

Efficacy of docusate called into question

HDL cholesterol key to fighting lymphoma

Researchers study innovative stem cell drug for treating localized cartilage damage

Findings could help explain prevalence of urinary tract infections in post-menopausal women

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

IntelliCell receives U.S. patent allowance for ultrasonic cavitation method

Hospital-based home care can work for children with cancer

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Gene therapy improves vision but does not halt progression of cell loss

Kaiser Permanente study examines increasing prevalence of undervaccination

Cordis presents two-year STROLL study results at ISET 2013

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News